Mesa Laboratories (MLAB)
Supplies sterilization, biopharma, calibration, and clinical-genomics tools for regulated health markets.
$134.63
After-hours close−0.02 (−0.01%)
At close$134.65(+2.11%)
In millions of USD, except per-share figures
| In millions | Q2 FY24Sep 2023 | Q3 FY24Dec 2023 | Q4 FY24Mar 2024 | Q1 FY25Jun 2024 | Q2 FY25Sep 2024 | Q3 FY25Dec 2024 | Q4 FY25Mar 2025 | Q1 FY26Jun 2025 | Q2 FY26Sep 2025 | Q3 FY26Dec 2025 | Q4 FY26Mar 2026 | Q1 FY27Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53 | 53 | 59 | 58 | 58 | 63 | 62 | 60 | 61 | 65 | 64 | 60 |
| Cost of revenue | 21 | 20 | 22 | 21 | 22 | 23 | 24 | 27 | 23 | 23 | 17 | 21 |
| Gross profit | 32 | 33 | 37 | 37 | 35 | 40 | 38 | 32 | 37 | 42 | 47 | 39 |
| 32 | 33 | 308 | 32 | 32 | 34 | 37 | 29 | 33 | 34 | 44 | 32 | |
| Research & development | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| 27 | 29 | 28 | 27 | 27 | 29 | 32 | 29 | 28 | 29 | 34 | 17 | |
| Selling & marketing | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 | 10 | 10 | 10 | 0 |
| General & administrative | 18 | 19 | 18 | 17 | 17 | 18 | 21 | 18 | 18 | 19 | 24 | 17 |
| Other expenses | 0 | 0 | 275 | 0 | 0 | 0 | 0 | −4 | 0 | 0 | 4 | 10 |
| Operating income | 0 | 0 | −271 | 6 | 4 | 6 | 1 | 3 | 5 | 8 | 3 | 7 |
| −1 | 2 | −4 | −2 | 0 | −8 | −1 | 4 | −3 | −3 | −4 | −3 | |
| Interest expense | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 |
| Other non-operating income | 0 | −4 | 2 | −1 | −3 | 5 | −2 | −6 | 0 | 0 | 4 | 0 |
| Income before tax | −1 | 2 | −275 | 4 | 4 | −2 | 0 | 7 | 2 | 5 | −2 | 4 |
| Income tax expense | 0 | 0 | −21 | 1 | 0 | −1 | 8 | 2 | 0 | 1 | 3 | 2 |
| Net income from continuing operations | −1 | 2 | −255 | 3 | 3 | −2 | −7 | 5 | 2 | 4 | −4 | 3 |
| Net income | −1 | 2 | −255 | 3 | 3 | −2 | −7 | 5 | 2 | 4 | −4 | 3 |
| EPS, basic | −$0.23 | $0.39 | −$47.20 | $0.63 | $0.63 | −$0.31 | −$1.31 | $0.87 | $0.45 | $0.66 | −$0.75 | $0.50 |
| EPS, diluted | −$0.23 | $0.39 | −$47.20 | $0.62 | $0.63 | −$0.31 | −$1.31 | $0.85 | $0.45 | $0.65 | −$0.75 | $0.49 |
| Weighted average shares, basic | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 |
| Weighted average shares, diluted | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 |
| EBITDA | 8 | 13 | −267 | 12 | 13 | 6 | 10 | 15 | 11 | 13 | 4 | 12 |
| Depreciation & amortization | 8 | 9 | 6 | 5 | 6 | 5 | 7 | 6 | 6 | 6 | 6 | 6 |
| EBIT | 0 | 4 | −273 | 7 | 7 | 1 | 3 | 9 | 5 | 8 | −2 | 7 |